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Mitochondrial dysfunctions accompany several neurodegenerative disorders and contribute to disease pathogenesis
among others in Parkinson’s disease (PD). Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) is
a major regulator of mitochondrial functions and biogenesis, and was suggested as a therapeutic target in PD.
PGC-1α is regulated by both transcriptional and posttranslational events involving also the action of growth factors.
Fibroblast growth factor-21 (FGF21) is a regulator of glucose and fatty acid metabolism in the body but little is
known about its action in the brain. We show here that FGF21 increased the levels and activity of PGC-1α and
elevated mitochondrial antioxidants in human dopaminergic cells in culture. The activation of PGC-1α by FGF21
occurred via the NAD+-dependent deacetylase Sirtuin-1 (SIRT1) subsequent to an increase in the enzyme, nicotinamide
phosphoribosyltransferase (Nampt). FGF21 also enhanced mitochondrial respiratory capacity in human dopaminergic
neurons as shown in real-time analyses of living cells. FGF21 is present in the brain including midbrain and is
expressed by glial cells in culture. These results show that FGF21 activates PGC-1α and increases mitochondrial
efficacy in human dopaminergic neurons suggesting that FGF21 could potentially play a role in dopaminergic
neuron viability and in PD.
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Parkinson’s disease (PD) is characterized by degeneration
of dopaminergic neurons in substantia nigra pars com-
pacta by mechanisms that are not fully understood
(Jenner and Olanow 2006; Gupta et al. 2008; Lees et al.
2009). Mitochondrial dysfunctions and changes in cell
metabolism with an altered growth factor signaling are
associated with the disease process in PD (Abou-Sleiman
et al. 2006; Lin and Beal 2006; Banerjee et al. 2009). Mito-
chondria influence a number of cellular functions ranging
from regulation of cell energy and metabolism, and the* Correspondence: dan.lindholm@helsinki.fi
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in any medium, provided the original work is pcontrol of intracellular calcium and cell death pathways
(Lindholm et al. 2004; Nunnari and Suomalainen 2012).
Mitochondria are also the major source of reactive oxygen
species (ROS) in the cell occurring as a consequence of
oxidative phosphorylation. In neurodegenerative disease
including PD increased levels of ROS are thought to
contribute to neuronal loss (Henchcliffe and Beal 2008;
Zhou et al. 2008).
Peroxisome proliferator activated receptor γ coactivator
1α (PGC-1α) is a transcriptional coactivator that is a mas-
ter regulator of mitochondrial biogenesis and cell viability
(Wu et al. 1999; Houten and Auwerx 2004; Lin et al.
2005). PGC-1α is also involved in cell defense against
oxidative stress by stimulating production of antioxi-
dant enzymes in the cell (St-Pierre et al. 2006). PGC-
1α has been studied mainly for its action in cell and
lipid metabolism and in metabolic disease such asan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Kleiner et al. 2012). In the brain gene deletion of PGC-
1α caused an increased susceptibility of neurons
against excitotoxic injury (St-Pierre et al. 2006; Cui
et al. 2006). A meta-analyses of PD patient samples in-
dicated that PGC-1α and its gene networks are poten-
tial therapeutic targets for early intervention in the
disease (Zheng et al. 2010). Recent studies with over-
expression of PGC-1α in mouse brain showed that it
exerts a protective effect on dopaminergic neurons in
the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
(MPTP) mouse model of PD (Mudo et al. 2012).
Available data shows that PGC-1α is regulated by
both transcriptional and posttranscriptional mechanisms
(Houten and Auwerx 2004; Lindholm et al. 2012). The
deacetylase Sirtuin-1 (SIRT1) can activate PGC-1α by
means of protein deacetylation as shown in different cell
types (Rodgers and Puigserver 2007; Nemoto et al. 2005).
SIRT1 is a NAD+-dependent enzyme that plays a crit-
ical role in the regulation of metabolism and the cell
response to nutrients and caloric restriction (Rodgers and
Puigserver 2007; Revollo et al. 2004; Lagouge et al. 2006;
Alcaín and Villalba 2009). Changes in SIRT1 has been
linked to aging (Alcaín and Villalba 2009; Mercken et al.
2013) and to metabolic and neurodegenerative diseases
(Mudo et al. 2012; Kim et al. 2007; Outeiro et al. 2008).
Fibroblast growth factor-21 (FGF21) a member of the
fibroblast growth factor 19 subfamily together with
FGF19 and FGF23 and is primarily expressed in the liver
(Nishimura et al. 2000). FGF21 has an endocrine func-
tion in the body and plays a role in cell metabolism by
stimulating glucose uptake (Kharitonenkov et al. 2005)
by influencing fatty acid metabolism (Potthoff et al.
2009) and by controlling lipoprotein receptor (LDLR)
levels and lipoprotein uptake in liver cells (Do et al.
2012). FGF21 was shown to increase PGC-1α in liver
and fat tissue (Potthoff et al. 2009; Fisher et al. 2012)
and to regulate energy homeostasis in adipocytes via the
SIRT1-PGC1 pathway (Chau et al. 2010). The expression
and functions of FGF21 in brain cells are so far unknown.
In this work, we have studied the role of FGF21 in the
regulation of PGC-1α and mitochondria in human
dopaminergic neurons. As a model we employed cul-
tured human dopaminergic neurons derived from mid-
brain neuronal precursor cells obtained from human
embryo (Lotharius et al. 2002). Results showed that
FGF21 influences the levels and activity of PGC-1α in
the human dopaminergic neurons by increasing SIRT1
and nicotinamide adenine dinucleotide (NAD+) in the
cells. The activation of PGC-1α was followed by in-
creased levels of the antioxidant enzymes, sodium dis-
mutase 2 (SOD2) and thioredoxin 2 (Trx2) and by an
enhanced mitochondrial respiratory capacity as revealed
by real-time in living neurons.Materials and methods
Cell culture
Human mesencephalon neuronal precursor cells (MESC2.10
cells) were cultured in poly-D-lysine (Sigma, St Louis,
MO, USA) coated flasks (75 cm2) in Dulbeccos modified
Eagle medium (DMEM)/F12 medium (Gibco, Invitrogen,
Calrsbad, CA, USA) supplemented with B27 (Gibco) and
Penicillin/streptomycin and human basic FGF 20 ng/ml
(Peprotech, Rocky Hill, NJ, USA). To induce neuronal dif-
ferentiation, cells were cultured for 6 days on poly-D-
lysine/laminin (Sigma) coated wells at a density of 30,000
cells /cm2 in a medium containing 1 μg/ml tetracyclin
(Sigma) (Lotharius et al. 2002; Di Liberto et al. 2012).
Medium was changed every second day and cell differen-
tiation was monitored by the expression of markers for
dopaminergic neurons such as tyrosine hydroxylase and
dopamine transporter. Human dopaminergic cells were
treated with 50 ng/ml FGF21 and analyzed as described
in the text. In some experiments 20 μM nicotinamide
(NAM) was used to the cells to inhibit SIRT1. Glial cul-
tures from newborn rodent brains were prepared and
cultured in 10% fetal calf serum in DMEM as described
previously (Lindholm et al. 1992; Mäkelä et al. 2010).
The human hepatocyte cell line (Huh7) was used as a
positive control for FGF21 expression (Do et al. 2012).
Immunoblotting
Differentiated MESC2.10 cells were treated with 50 ng/
ml FGF21 (R&D Systems, Minneapolis, MN, USA) for
24 h and cells were lysed in RIPA buffer containing
150 mM NaCl, 1% NP-40, 0,25% sodium deoxycholate,
50 mM Tris-HCl pH 7.4, and 0,1% sodium dodecyl sul-
fate (SDS). Immunoblotting was done essentially as de-
scribed (Mudo et al. 2012; Do et al. 2012; Korhonen
et al. 2001; Sokka et al. 2007). In brief, 30 μg of protein
was run on SDS-PAGE and transferred to Hybond-C
Extra nitrocellulose membrane (Amersham Biosciences,
Buckinghamshire, UK). The membrane was blocked in
5% non-fat milk-Tris buffered saline (TBS) for 1 h and
room temperature and primary antibodies were added
overnight at +4˚C. The antibodies used were: anti-SIRT1
(diluted 1:1000; Cell Signaling Technology, Danvers, MA,
USA), anti-PBEF/NAMPT (1:1000; Abcam, Cambridge,
UK), anti-SOD2 (1:5000; AbFrontier, Seoul, Korea),
anti-Trx2 (1:1000; AbFrontier), anti- PGC-1α (1:5000;
Calbiochem, San Diego, CA, USA), anti- cytochrome
oxidase IV (COX IV, 1:2000; Abcam), anti-mitochondrial
transcription factor A (TFAM, 1:1000; Abcam), anti-
FGF21 (1:3000; Novus Biologicals, Littleton, CO, USA)
and anti-β-actin (1:5000; Sigma). The membranes were
washed with TBS-5% Tween20 buffer and appropriate
horseradish peroxidase (HRP)-conjugated secondary anti-
bodies (1:2500; Jackson ImmunoResearch, West Grove,
PA, USA) were added for 1 h at room temperature. Super
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Waltham, MA, USA) was used for visualization of the
bands, and ImageJ software for their quantification.
Different brain regions of adult mouse were dissected
under stereomicroscopy and frozen in cooled isopentane
as described before (Mudo et al. 2012). Tissue pieces
were homogenized in cold RIPA buffer containing also
10 μg/ml aprotinin, 10 μg/ml leupeptin, 0.1 mM phenyl-
methylsulfonyl fluoride, 100 μM sodium orthovanadate
(Na3VO4) and 1 mM ethylenediaminetetraacetic acid
(EDTA; Sigma-Aldrich, St. Louis, MO, USA). The hom-
ogenate was left on ice for 30 min and centrifuged at
10,000 × g for 15 min at 4°C to yield supernatant frac-
tions that were stored at−80°C until use. To obtain
enough material, the two SN were pooled. 30-40 μg of
protein was subjected to immunoblotting as above using
primary antibodies anti-FGF21 (1:3000) and β-actin as
control. The membrane was processed as above using
secondary antibodies and visualisation of bands was
made by enhanced chemiluminescence.Immunoprecipitation
Experiments were done essentially as described (Mudo
et al. 2012; Revollo et al. 2004) using lysates from human
dopaminergic cells treated with 50 ng/ml FGF21 for
24 h alone or together with 10 mM nicotinamide (NAM;
Acros organics, Geel, Belgium). In brief, 1,5 μg of anti-
PGC-1α antibody (Calbiochem) was added to 500 μg of
cell lysates overnight at +4˚C under constant rotation.
50 μl of Protein G-agarose (Roche, Basel, Switzerland)
was then added to the samples and incubated for 6 h.
Beads were washed three times with RIPA buffer and
samples were run on 8% SDS-PAGE, followed by transfer
and immunoblottings as described above using first anti-
acetylated lysine antibodies (1:1000; Cell signaling
technology) and then anti-PGC-1α antibodies. The quan-
tifications of the bands were done using ImageJ software.
The degree of acetylation of PGC-1α is an index for the
activity of this protein in the cell (Mudo et al. 2012;
Rodgers and Puigserver 2007).Luciferase assay
Cells were transfected with 0,5 μg of the PGC-1α–lucif-
erase reporter constructs or the control pGL3 promoter
constructs together with 0,025 μg Renilla pRL-TK
plasmid using Fugene (Promega, Madison, WI, USA).
Cells were incubated for 2 days in the differentiation
medium and 50 ng/ml FGF21 was added for an additional
24 h. Luciferase activity was measured using the Dual-
Luciferase reporter Assay (Promega) and a GLOMAX 20/
20 luminometer (Promega) as described previously (Mudo
et al. 2012; Kairisalo et al. 2009). The values were normal-
ized to those of Renilla.Determination of NAD+/NADH levels
To analyze NAD+/NADH level in cells the absorbance
at 450 nm was measured using Multiscan MS Version
3.0 spectrophotometer following the assay kit as pro-
vided by the manufacturer (Abcam).
Real-time analyses of mitochondrial respiratory capacity
in human dopaminergic neurons
Cells were plated on Seahorse 96well plate (Seahorse
Bioscience, Boston, MA USA) and differentiated for 5
days followed by a 24 h-stimulation with 50 ng/ml FGF21.
Medium was changed to HCO3-free DMEM (Sigma) con-
taining 10 mM pyruvate, 1 mM l-glutamine and 10 mM
glucose 1 h prior to analyses and keeping cells at +37˚C
without CO2. Oxygen consumption rate (OCR) in dopa-
minergic neurons was determined in real-time using the-
Seahorse XFe96 analyzer (Seahorse Bioscience) by
determining oxygen consumption as response to the
addition of various chemicals. Three 3 min cycles were
run for every measurement and the Mitostress kit
(Seahorse) was used containing the following com-
pounds: 1 μM Oligomycin (ATP synthase inhibitor),
0,8 μM Carbonyl cyanide 4-(trifluoromethoxy)phenylhy-
drazone (FCCP) (mitochondrial uncoupler), 1 μM Rote-
none (complex I inhibitor of the respiratory chain) and
Antimycin A (complex III inhibitor).
Mitochondrial DNA copy number
DNA was isolated from human dopaminergic neurons
using QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany)
according to manufacturer’s protocol. The relative mito-
chondrial DNA (mtDNA) copy number was measured
using quantitative PCR and comparing the ratio of mtDNA
to nuclear DNA and the method described previously (Xie
et al. 2013). In brief, the mitochondrially encoded NADH
dehydrogenase 1 (ND1 gene) was used for quantifying
mtDNA and human globulin (HGB) gene for nuclear DNA.
The primer sequences used were: forward primer ND1-F:
5′-CCT AAA ACC CGC CAC ATC T-3′, reverse primer
ND1-R: 5′-GAG CGA TGG TGA GAG CTA AGG T-3′;
forward primer HGB-F: 5′-GTG CAC CTG ACT CCT
GAG GAG A-3′, and reverse primer HGB-R: 5′-CCT
TGA TAC CAA CCT GCC CAG-3′. The PCR reaction
mixture contained 5 ng DNA and 200 nmol/l of forward
and reverse primers in 1X SYBR Green Mastermix
(Roche). The reaction was carried out at 95˚C for 10 min
followed by at 95˚C for 15 s and 60˚C for 1 min using 40
cycles. Each sample was run in triplicates on a 96-well
plate and water was used as negative control. Quantitative-
PCR (qPCR) amplification was performed using Light Cy-
cler 480 II instrument (Roche) as described (Do et al. 2012;
Hyrskyluoto et al. 2013). The ratio of mtDNA to nuclear
DNA reflects the concentration of mtDNA per dopamin-
ergic cell.
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Human dopaminergic neurons were stimulated with
50 ng/ml FGF21 for 24 h, fixed with 2,5% glutaraldehyde
in PBS for 1 h at room temperature, and washed two
times for 1 h with H2O. Postfixation was done using 1%
osmiumtetroxide. The embedding and sectioning proce-
dures were done essentially as described before (Korhonen
et al. 2008). The sections were stained with lead citrate
and uranyl acetate and viewed using a Jeol JEM-1400
transmission electron microscope (Jeol Ltd., Tokyo, Japan)
equipped with Gatan Orius SC 1000B bottom mounted
CCD-camera (Gatan Inc., USA). Mitochondria identified
in the EM pictures of the cells were marked manually and
the relative surface area was calculated using the ImageJ
software. Results were pooled from different sections of
control and FGF21-treated cells and the density of mito-
chondria was compared.Quantification and statistics
Immunoblots were quantified with ImageJ quantification
software. Results are expressed as percentage of controls
and statistical analyses were performed using one-way
analysis of variance (ANOVA) and Bonferroni’s multiple
comparison tests. Values are given as means ± SD and
p < 0.05 was considered as statistically significant.Results
FGF21 increases levels and deacetylation of PGC-1α in
cultured human dopaminergic neurons
In this work we used midbrain progenitor (MESC2.10)
cells from human embryonic brain (Lotharius et al.
2002) that were further differentiated into dopamin-
ergic neurons in culture (Figure 1A). Treatment of the
cells with 50 ng/ml FGF21 for 24 h led to an increase
in PGC-1α as shown by immunoblotting (Figure 1B).
To clarify whether this involved increased gene ex-
pression we used the PGC-1α-promoter linked to a lu-
ciferase reporter gene. Data showed that the gene
activity of the PGC-1α promoter was increased by
FGF21 with no changes in the activity of the pGL3
basic-promoter used as control (Figure 1C). There was
also an increase in PGC-1α mRNA levels in FGF21-
treated dopaminergic neurons using quantitative PCR
(data not shown). To study whether FGF21 may ac-
tivate PGC-1α we performed immunoprecipitation
experiments followed by immunoblotting using anti-
PGC-1α and anti-acetylated lysine antibodies. Data ob-
tained showed that the relative degree of acetylation of
PGC-1α decreased in cells treated with FGF21 as com-
pared to control (Figure 1D). Collectively these data
indicate that FGF21 can increase both the level and
the activation status of PGC-1α in the human dopa-
minergic neurons.FGF21 increases Nampt and NAD+ levels and SIRT1 in the
dopaminergic neurons
PGC-1α can be post-transcriptionally modified in cells
that affect its properties as gene coactivator (Houten
and Auwerx 2004; Lin et al. 2005). SIRT1 is known to
deacetylate PGC-1α increasing its activity (Rodgers and
Puigserver 2007). We were therefore interested to study
possible effects of FGF21 on SIRT1 in the human dopa-
minergic neurons. Data showed that stimulation of cells
for 24 h with 50 ng/ml FGF21 increased the levels of
SIRT1 as analyzed by western blot (Figure 2A). We also
observed that FGF21 treatment increased the levels of
Nampt, which is the rate-limiting enzyme in NAD+ bio-
synthesis (Figure 2B). FGF21 also increased the NAD+
levels in the dopaminergic neurons as shown using the
NAD+/NADH assay (Figure 2C). This shows that FGF21
increases Nampt and the NAD+ levels in the dopamin-
ergic neurons that subsequently activate SIRT1 and
PGC-1α in these cells. To substantiate this further, we
incubated the neurons in the presence of the SIRT1-
inhibitor NAM that increased the degree of acetylation
of PGC-1α in the cells (Figure 2D). NAM also counter-
acted the deacetylation of PGC-1α induced by FGF21 in
these neurons (Figure 2D). Collectively these results
show that FGF21 influences the Nampt/SIRT1 pathway
in the human dopaminergic neurons leading to the acti-
vation of PGC-1α.
FGF21 increases mitochondrial antioxidants in human
dopaminergic neurons
We have previously shown that overexpression of PGC-
1α in transgenic mice led to an increase in the levels of
SOD2 and Trx2, two mitochondrial antioxidants, in the
substantia nigra harboring the dopaminergic neurons
(Mudo et al. 2012). We therefore studied whether these
antioxidants were also increased in human dopaminergic
neurons after FGF21 treatments. Data showed that
SOD2 and Trx2 were both significantly upregulated by
FGF21 in these neurons (Figure 3A-C). This suggests
that FGF21 via activation of PGC-1α can increase these
mitochondrial antioxidants that may contribute to neu-
roprotection against oxidative stress.
FGF21 stimulates mitochondrial respiratory capacity of
human dopaminergic neurons
To study the effect of FGF21 on mitochondrial functions
in dopaminergic neurons further we analyzed the cells
in real-time using the Seahorse equipment as described
in Methods. Data showed that the human dopaminergic
neurons stimulated with FGF21 had an increased basal
respiration and a higher maximal respiratory capacity as
compared to control cells (Figure 4A-B). This result to-
gether with data on the antioxidants indicates that
FGF21 is able to increase the mitochondrial efficacy and
Figure 1 Effect of FGF21 on the expression and activation of PGC-1α in human dopaminergic neuron. Human dopaminergic neurons
differentiated from midbrain progenitor cells were cultivated as described in Materials and methods. Cells were treated with 50 ng/ml FGF21 for
24 h as indicated below. (A) Left, immunoblot showing expression of tyrosine hydroxylase (TH) and dopamine transporter (DAT) in the human
dopaminergic cells. β-actin was used as control. Right, phase contrast pictures. There was no significant difference in morphology between
control and FGF21 treated cells. Scale bar. (B) Left, immunoblot. β-actin was used as control. The levels of PGC-1α were increased by FGF21. Right,
quantification was done using ImageJ software. Values are means ± SD, n = 4, ***p < 0.001 for FGF21 vs C. (C) Gene promoter assays. Cells were
transfected with the pGL3 basic plasmid and the PGC-1α promoter plasmids linked to a luciferase reporter. Cells were stimulated with FGF21 for
24 h and the luciferase activity was measured and corrected for that of Renilla as described as described in Methods. FGF21 enhanced PGC-1α
gene activity but not that of the control pGL3 promoter. Values are means ± SD, n = 4, *p < 0.05 for FGF21 vs controls. (D) Immunoprecipitation
experiments. PGC-1α was immunoprecipitated from control and FGF21-treated cells followed by immunoblotting as described in Methods. The
degree of acetylation of PGC-1α was analyzed using the anti-acetylated lysine antibody. Total amount of PGC-1α in the immunoprecipitate was
analyzed using anti- PGC-1α antibodies. Values are means ± SD, n = 4, *p < 0.05 for FGF21 vs C.
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minergic neurons. We were also interested to investigate
whether the number and biogenesis of mitochondria
could be altered by FGF21 in the cultured human dopa-
minergic cells. To clarify this we first analyzed the levels
of TFAM and of COX IV as markers for mitochondria.
Data showed that neither of these proteins was increased
by a 24 h-FGF21 treatment of dopaminergic neuronscompared with controls (Figure 4C). Estimation of the
mtDNA content using qPCR revealed also no change in
the ratio of mtDNA to nuclear DNA after FGF21 stimula-
tions indicating an equal number of organelles in control
and FGF21-treated dopaminergic neurons (Figure 4D). To
substantiate this we also studied the morphology of mito-
chondria using electron microscopy (EM) (see Methods).
Measurements of the relative mitochondrial area from
Figure 2 FGF21 increases SIRT1 and Nampt and the level of NAD+ in human dopaminergic neurons. Human dopaminergic neurons were
treated with 50 ng/ml FGF21 for 24 h as indicated below. (A-B) Immunoblots. β-actin was used as a control. The levels of SIRT1 (A) and Nampt
(B) were increased by FGF21. Left, immunoblots. Right, quantifications using ImageJ. Values are means ± SD, n = 4, ***p < 0.001 and *p < 0.05 for
FGF21-treated vs C. (C) The ratio of NAD+ to NADH in the dopaminergic neurons was measured as described in Methods. FGF21 increased NAD+
levels in the neurons. Values are means ± SD, n = 4, *p < 0.05 for FGF21 vs C. (D) Immunoprecipitation experiments. Cells were stimulated with
FGF21 for 24 h in the absence or presence of 20 μM NAM to inhibit SIRT1. The degree of acetylation of PGC-1α was analyzed as above. Left, im-
munoblot. Right, quantification. FGF21 decreased PGC-1α acetylation in control cells but not in NAM treated cells. There was also an increase in
acetylated PGC-1α due to SIRT1 inhibition as compared with controls. Values are means ± SD, n = 4, *p < 0.05 for FGF21 vs C.
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trol and FGF21-treated cells (Figure 4E-F). Taken together
these results show that FGF21 can increase the efficacy of
the mitochondria but that this is not related to an in-
creased mitochondria number in the dopaminergic cells
after treatment with FGF21.
FGF21 is expressed in the midbrain and by glia cells
in culture
To study whether FGF21 is present in brain tissue, we per-
formed immunoblotting experiment using samples from
adult rodent brain and antibodies against FGF21. Data
showed that FGF21 is present in different brain regions in-
cluding substantia nigra and striatum that contain the cell
bodies and the terminals of the midbrain dopaminergic
neurons respectively (Figure 5A). Studies in vitro showed
that primary glial cultures obtained from neonatal rat brain
expressed FGF21 as shown by immunoblotting (Figure 5B).
The relative levels of FGF21 expressed by these cellscorrespond to those found in the human hepatocyte Huh7
cell line (Figure 5B). This data suggest that glial cells can
produce FGF21 as studied in vitro. Immunohistochemical
analyses employing the anti-FGF21 antibody were not con-
clusive, and the precise localization of FGF21 in different
brain cells will require more studies in the future.
Discussion
FGF21 is a growth factor that has been studied mainly for
its effects on metabolism and cell responses in peripheral
cells. The present work demonstrates that FGF21 can in-
crease both the mitochondrial respiratory capacity and
PGC-1α in human dopaminergic neurons. These two ef-
fects of FGF21 in the human dopaminergic neurons are
probably interconnected and related to the activation of
PGC-1α by this growth factor. PGC-1α is known to be a
major regulator of mitochondria biogenesis and functions
via regulation of gene expression (Houten and Auwerx
2004; Lin et al. 2005). PGC-1α also takes part in protection
Figure 3 FGF21 elevates mitochondrial antioxidants in the dopaminergic neurons. Human dopaminergic neurons were treated with 50 ng/
ml FGF21 for 24 h followed by immunoblotting. (A) Immunoblots. β-actin was used as a control. FGF21 increased the levels Sod2 and Trx2 that
are antioxidants localized to mitochondria. (B-C) Quantification. Sod2 (B) and Trx2 (C) increased in FGF21-treated neurons. Values are means ± SD,
n = 4, **p < 0.01 or *p < 0.05 for FGF21 vs C.
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human metabolic disorders and degenerative diseases (St-
Pierre et al. 2006). In line with this we found that FGF21
increased the levels of the antioxidant enzymes SOD2 and
Trx2 localized to mitochondria in the human dopamin-
ergic neurons. Previous studies using transgenic mice
overexpressing PGC-1α in dopaminergic neurons alsoshowed an increase in these antioxidants in the midbrain.
Furthermore, the compound resveratrol acting via the
SIRT1/ PGC-1α can also stimulate SOD2 and Trx2 levels
both in cultured neurons and in the brain (Mudo et al.
2012; Kairisalo et al. 2011). As shown in vivo, the increase
in mitochondrial antioxidants by PGC-1α was accompan-
ied by cell protection of dopaminergic neurons against the
Figure 4 Effect of FGF21 on the mitochondria respiratory capacity and mitochondria number in human dopaminergic neurons. Human
dopaminergic neurons were stimulated with 50 ng/ml FGF21 and analyzed further as indicated below. (A) Oxygen consumption rate (OCR) in
human dopaminergic neurons was measured in real-time using the Seahorse equipment as described in Methods. Typical graphs after addition
of the various inhibitors are shown. (B) Quantification. Basal and maximum respiration (OCR) were increase in cells treated with FGF21 as was the
spare respiratory capacity. Values are means ± SD, n = 4. ***p < 0.001 for FGF21 vs C. (C) Immunoblots. β-actin was used as control. The mitochondrial
proteins TFAM and COX IV showed no significant changed in dopaminergic neurons treated with FGF21. (D) The mitochondrial DNA (mtDNA) copy
number was analyzed using quantitative PCR as described in Methods. There was no change in the relative ratio of mtDNA to nuclear DNA reflecting
an equal number of mitochondria in control and FGF21-treated dopaminergic cells. (E-F) Mitochondrial surface area. Left, control and FGF21 treated
cells were analyzed by electron microscopy and the relative mitochondrial area was calculated from EM pictures as described in Methods. There were
no significant changes in the mitochondrial surface area between control and FGF21 treated cells. Values are means means ± SD, n = 4. Right, typical
EM pictures of control and FGF treated cells.
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2012). Together these results show that PGC-1α is an im-
portant factor in regulation of dopaminergic neuron via-
bility and that growth factors like FGF21 may act via the
induction of PGC-1α and its downstream pathways in the
neurons.
The mechanisms by which PGC-1α are regulated have
been studied in different cell types and shown to be ra-
ther complex (Houten and Auwerx 2004; Lindholm
et al. 2012). Available data indicates that both transcrip-
tional and post-transcriptional events are involved in the
control of this protein. In this work we studied the mech-
anism by which FGF21 influences PGC-1α in neurons
using human dopaminergic cells as a model system
(Lotharius et al. 2002; Di Liberto et al. 2012). Data showed
that FGF21 increased the regulatory protein SIRT1 with
the ability to de-acetylate and activate PGC-1α. NAD+
levels are crucial in the control of biosynthetic reactions
and cell metabolism that occurs partly via SIRT1. Weobserved that FGF21 elevated NAD+ in the dopaminergic
neurons following an increase in the enzyme Nampt that
is rate limiting in the biosynthesis of NAD+ from NAM
(Revollo et al. 2004; Yang et al. 2006). These results
show that FGF21 can affect SIRT1 activity via an in-
crease in the Nampt/NAD levels in the dopaminergic
neurons. Previous studies have shown that the expres-
sion of Nampt also called pre-B-cell colony-enhancing
factor (PBEF) or visfatin can be induced by nutrient re-
striction and by cytokines (Yang et al. 2006; Wang et al.
2006). These studies have been concerned mainly with
fibroblast, vascular smooth cells or with pancreatic β-
cells. In this work we show that the Nampt-SIRT1 path-
way is also active in neurons and can be regulated by
FGF21 signaling. These results in dopaminergic neu-
rons add to previous data showing an involvement of
Nampt in the regulation of metabolic responses, in-
flammation, and cell differentiation in peripheral cells
(Garten et al. 2009). Given its role in the activation of
Figure 5 FGF21 is expressed in brain tissue and by glia cells in culture. (A) Brain regions from adult mice were dissected and subjected to
immunoblotting using anti-FGF21 antibodies. β-actin was used as control. FGG21 is present in all brain areas. Two bands are detected represent-
ing the precursor and processed, mature form of FGF21 respectively. SN, substantia nigra; ST, striatum; HC, Hippocampus; CX, Cortex. (B) Immuno-
blot. Glia cell cultures were made from neonatal rat brain as described in Methods. Immunoblotting of cell lysates were performed using anti-
FGF21 antibodies. The human hepatocyte cell line (Huh7) was used as a positive control. Note the presence of FGF21 in both cell types.
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to study the regulation of Nampt in animal models of
PD and after treatment with other factors.
To prove the point that FGF21 can stimulate mito-
chondrial functions in the dopaminergic neurons we per-
formed a real-time analysis of the cells using the Seahorse
equipment. Data showed that FGF21 is able to increase
the mitochondrial respiratory capacity of the human
dopaminergic neurons. Though not formally proven, we
suspect that this effect is due to the activation of PGC-
1α by FGF21 in these neurons. This data made in neu-
rons is in line with previous results on the regulation of
mitochondrial functions by the SIRT1/ PGC-1α in muscle
cells (Gerhart-Hines et al. 2007). Furthermore, we here
also analyzed whether the copy number of these organ-
elles increased by this growth factor. For this we studied
the mitochondrial DNA copy number using PCR, and
the expression of TFAM a regulator of mitochondrial
biogenesis proteins and COX IV as a protein of the re-
spiratory chain. Together the results showed that there
was no significant change in any of these parameters
following FGF21 treatment. This suggests that the copy
number is not altered by FGF21 and that the respira-
tory capacity is mainly increased in the dopaminergic
neurons by this growth factor. A constant level of mito-
chondria may arise from changes in biogenesis and
degradation of the organelle that balance each other. Inthe future it will be interesting to study whether FGF21
may also affect the dynamics of mitochondria in dopa-
minergic neurons.
Previous studies have shown that several members of the
large fibroblast growth factor (FGF) gene family are also
expressed in the central nervous system (Itoh and Ornitz
2011). The FGFs have important functions both during de-
velopment and in the mature brain (Itoh and Ornitz 2011;
Mudò et al. 2009; Lahti et al. 2012). So far little is known
about the expression of FGF21 in the brain. Using immu-
noblots we show here that FGF21 is expressed in various
brain regions of adult mouse to an appreciable amount.
Studies on primary brain cell cultures showed that glial cells
can produce FGF21 in substantial amounts at least in vitro.
Immunohistochemical analyses using the FGF-21 anti-
bodies proven hard to perform and gave ambiguous results.
Further studies using other antibodies or in situ
hybridization experiments are therefore required to deter-
mine which cell types specifically express FGF21 in the
brain.
One of the issues not addressed in this study is the nature
of the receptors mediating the effects of FGF21 on human
dopaminergic neurons. There are four types of FGF recep-
tors, and FGF21 was shown to interact with at least FGF
receptors 1-3 (Suzuki et al. 2008; Kharitonenkov et al.
2008). In addition, the protein β-Klotho is required for
FGF21 to exert its biological actions (Suzuki et al. 2008;
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case for all types of cells (Tomiyama et al. 2010). Previ-
ous studies using in situ hybridization revealed an ex-
pression of Fibroblast growth factor receptor 1 (FGFR1) in
substantia nigra neurons in adult rats (Belluardo et al.
1997). However fewer data are available on human neu-
rons, and the receptors by which FGF21 stimulates hu-
man dopaminergic neurons warrant further studies in
the future.
The present study showing effects of FGF21 in dopa-
minergic neurons may have further physiological rele-
vance for the regulation of cell signaling events and
metabolism in brain cells. It has been proposed that
neurodegeneration is accompanied by changes in neur-
onal metabolism or dysfunctional cell signaling that
may be alleviated by the use of various drugs or growth
factors (Patrone et al. 2013). FGF21 is a metabolic
regulator has many beneficial effects on cell meta-
bolism and in human metabolic diseases. The expres-
sion of FGF21 can be induced by prolonged fasting
(Kharitonenkov et al. 2005; Inagaki et al. 2007) and
FGF21 may also penetrate into brain tissue (Hsuchou
et al. 2007). It was recently also shown using transgenic
mouse that FGF21 is able to increase the life span of
the animals probably due to altered cell signaling cas-
cades (Zhang et al. 2012).
In conclusion, the present study shows that dopamin-
ergic neurons respond to FGF21 by enhancing the mito-
chondrial capacity and altering gene pathways regulated
by PGC-1α in these cells. These results suggest that
FGF21 may be of value in considering neuroprotection
strategies for PD. In the future it would be interesting to
study the potential benefits can be afforded by FGF21 in
different neurological disorders.
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